+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 22 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the long-term safety of lonapegsomatropin in children with growth hormone deficiency who are already being treated with this medication. This study is observational and aims to gather real-world safety data over time after the drug has been authorized for use. The focus is on monitoring potential risks such as the development of tumors and type 2 diabetes over a period of five years. Participants receive lonapegsomatropin, administered once weekly by subcutaneous injection as part of their usual care. The study does not involve additional interventions but observes patients who are already treated with this therapy. The observational period extends for at least five years to collect safety data and compare it with historical information from previous studies. During the study, researchers will monitor for the occurrence of benign and malignant tumors, type 2 diabetes, and other adverse events affecting the kidneys, liver, immune system, and nervous system. They will also track medication errors and measure the response of Insulin-like Growth Factor-1 IGF-1 to treatment. Participants are followed up regularly to collect this information, with the study lasting until March 2033.

Age: 1Year - 18YearsAll Genders
27 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called brenipatide when added to standard treatment for adults with major depressive disorder. The study compares brenipatide plus standard care to a placebo plus standard care to see if it can delay the return of major depressive symptoms. This is a phase 3, randomized, double-blind trial sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all given by subcutaneous injection along with their standard care. The study has four periods a screening phase lasting about one month, a combined treatment and post-treatment phase lasting at least 12 months, and a safety follow-up period of about two months. The total participation time may vary and can be shortened if symptoms worsen or if participants withdraw. During the study, participants will self-inject the study medication and keep electronic and paper diaries, complete questionnaires, and attend scheduled visits. Researchers will measure the time to relapse of major depressive disorder symptoms as the main outcome. Other assessments include changes in body weight, depression severity, functional impairment, anxiety levels, quality of life, and presence of treatment-related antibodies. Safety monitoring will continue throughout the study and follow-up periods.

Age: 18Years - 75YearsAll GendersPhase 3
170 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with cutaneous sarcoidosis, a condition affecting the skin. This phase 23 randomized, double-blind, placebo-controlled trial aims to study different doses of brepocitinib to understand how it impacts the diseases activity and morphology. The study is sponsored by Priovant Therapeutics, Inc. and focuses on measuring adverse events and improvements in skin condition over 16 weeks. Participants will be randomly assigned to receive one of several doses of oral brepocitinib or a placebo. The study is divided into two parts Part 1 compares two dose levels of brepocitinib against placebo, and Part 2 evaluates one dose level against placebo. Treatment lasts for 16 weeks, during which participants take the study drug or placebo orally. The trial uses a triple-blind design, meaning participants, investigators, and others involved do not know which treatment is being given. During the 16-week treatment period, participants will be regularly monitored for treatment-emergent adverse events and serious side effects using CTCAE v5.0 criteria. The main measurement of effectiveness is the reduction in the Cutaneous Sarcoidosis Activity and Morphology Instrument Activity CSAMI-A score from baseline to Week 16. Secondary measures include changes in CSAMI-A scores and the proportion of participants achieving low disease activity. Safety and treatment effects are closely observed, with the study completion planned for the end of 2029.

Age: 18Years +All GendersPhase 2Phase 3
44 locations
S

Actively Recruiting

Researchers are evaluating LY4005130, an intravenous drug, to see how well it is tolerated and what side effects may occur in adults with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled study compares LY4005130 to a placebo over about 48 weeks, including screening. Participants must have NSV diagnosed for at least 3 months with specific body surface area involvement. Participants receive either LY4005130 or placebo intravenously during the treatment period. The study includes a 24-week treatment phase where the drug or placebo is administered, and blood tests are done to understand how the body processes the drug and how it affects the skin condition. The study drug is given through the vein in the arm. During the study, participants will have assessments including blood tests, skin evaluations using Vitiligo Area Scoring Indexes F-VASI and T-VASI, and skin biopsies to measure gene expression changes. Researchers will monitor safety, drug levels in the blood, and treatment effects up to 48 weeks. The main outcome is the percentage of participants achieving significant improvement in facial vitiligo area at week 24.

Age: 18Years - 75YearsAll GendersPhase 2
35 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of D-2570 in adults with moderate to severe plaque psoriasis. This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to assess how well D-2570 works and how safe it is for participants with this skin condition. The study focuses on participants who have had stable disease without major flares for at least six months. Participants will be randomly assigned to receive either a low dose or a high dose of D-2570 tablets, or placebo tablets that look identical. Treatments are given over a 12-week period, during which participants and researchers will monitor their responses to the study drug or placebo. The study uses a quadruple-blind design where participants, care providers, investigators, and outcome assessors do not know which treatment is given. During the study, participants will undergo various assessments including measurement of psoriasis severity using the Psoriasis Area and Severity Index PASI, Physicians Global Assessment PGA, and evaluation of body surface area affected. The primary outcome is improvement in PASI-90 after 12 weeks of treatment or placebo. Laboratory tests and safety monitoring will also be performed throughout the study to track any changes and ensure participant safety.

Age: 18Years - 70YearsAll GendersPhase 2
20 locations
E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of remibrutinib in adults with severe chronic pruritus of unknown origin CPUO, a condition characterized by severe itching without a known cause. This global, phase 3, randomized, double-blind, placebo-controlled trial aims to establish how remibrutinib performs compared to placebo in treating this condition. Participants will go through four study periods over up to 60 weeks. After a screening period of up to 4 weeks, they will enter a 24-week double-blind treatment phase receiving either remibrutinib or placebo. Following this, all participants receive open-label remibrutinib for 28 weeks, including those initially on placebo who switch at Week 24. The study concludes with a 4-week treatment-free safety follow-up. During the study, participants will be regularly assessed for itch severity using the Worst Itch Numerical Rating Scale and Patient Global Impression of Severity sleep disturbance related to itching will also be measured. Safety will be monitored by tracking adverse events throughout the 52-week treatment period. Participants adherence and response to treatment will be closely followed, with all evaluations scheduled at specific time points including baseline, Week 4, Week 12, and Week 24.

Age: 18Years +All GendersPhase 3
10 locations
E

Actively Recruiting

Researchers are studying the effects of Deucravacitinib BMS-986165 in adolescents aged 12 to 17 years with moderate to severe plaque psoriasis. The study aims to assess the drugs effectiveness, safety, and how it behaves in the body. This phase 3 trial is designed as a randomized, double-blind, placebo-controlled investigation to provide clear evidence of the drugs impact in this younger population. Participants are randomly assigned to receive either Deucravacitinib or a placebo following specified dosing schedules. The study involves a parallel group design where the treatment is given on specified days. The trial will monitor participants closely over time to evaluate treatment responses and any side effects, especially focusing on improvements in psoriasis severity and skin condition. During the study, participants will have regular assessments including measurement of psoriasis severity by Psoriasis Area and Severity Index PASI and Physicians Global Assessment sPGA, body surface area affected, itch severity, and quality of life. Safety monitoring includes checking for adverse events, laboratory tests, physical exams, vital signs, and vaccine antibody levels. The study also tracks growth and sexual maturation over up to five years, providing long-term data on drug safety and participant health.

Age: 12Years - 17YearsAll GendersPhase 3
133 locations
E

Actively Recruiting

The trial investigates the safety and effectiveness of ruxolitinib cream in treating children with nonsegmental vitiligo, a condition causing loss of skin pigment. It is a Phase 3, randomized, double-blind study aimed at evaluating how well this topical treatment works in pediatric participants aged 2 to 11 years with limited body surface affected by vitiligo. Participants are randomly assigned to receive either ruxolitinib 1.5% cream or a matching vehicle cream, both applied twice daily as a thin film to the affected skin areas. The study measures improvements in facial and total body vitiligo using specific scoring indexes over 24 and 52 weeks. Participants must stop other vitiligo treatments during the trial and are monitored for safety throughout. Throughout the study, participants undergo assessments including evaluation of skin pigment improvement using Facial Vitiligo Area Scoring Index F-VASI and Total Body Vitiligo Area Scoring Index T-VASI. Safety is tracked by recording any adverse events up to 30 days after treatment. Pharmacokinetic tests measure drug concentration at multiple time points. The total study duration extends up to nearly four years, with ongoing follow-up to evaluate treatment effects and safety.

Age: 2Years - 11YearsAll GendersPhase 3
98 locations
R

Actively Recruiting

Researchers are evaluating whether spesolimab helps adults with ulcerative pyoderma gangrenosum PG, a skin condition causing ulcers. The study focuses on whether spesolimab leads to the closure of PG ulcers and compares this with a placebo. This phase 3 clinical trial is randomized, double-blind, and placebo-controlled, enrolling adults with at least one ulcer between 5 cm and 80 cm in size. Participants are randomly assigned to receive either spesolimab or a placebo infusion every 4 weeks. In the first part of the study, all participants also take corticosteroid medicine by mouth for 8 weeks. In the second part, those without open ulcers are again randomly assigned to spesolimab or placebo, while participants with open ulcers receive spesolimab. The study includes two treatment phases to evaluate the effects under different conditions. Participants stay in the trial for about 1.5 years, attending around 20 study visits. During visits, doctors examine the skin for signs of PG, monitor overall health, and watch for any side effects. The main outcome is the complete closure of the target PG ulcer up to week 26, confirmed at a later visit. Secondary outcomes include pain reduction and quality of life improvements. The study compares results between groups to assess the treatments impact and monitors participants safety throughout.

Age: 18Years +All GendersPhase 3
104 locations
A

Actively Recruiting

This research aims to gather long-term evidence on the safety and effectiveness of SKYTROFA lonapegsomatropin in patients with growth hormone deficiency who are receiving routine clinical care. The study focuses on understanding how patients respond to this treatment over time without altering their usual medical management. It is a non-interventional observational study conducted across multiple centers in the USA. Patients will continue their regular treatment with SKYTROFA as managed by their healthcare providers, with no additional visits, examinations, or tests required beyond standard clinical care. The study will collect data from clinical outcome assessments COAs to evaluate treatment results and safety over a period of five years. No experimental interventions or placebos are involved. Participants will be monitored through their routine clinical visits, with researchers reviewing their health status and treatment effectiveness using standard assessments. The primary outcomes include measuring safety and treatment effectiveness over five years, along with evaluating clinical outcomes through COAs. This approach allows for natural observation of patient experiences without extra procedures or disruptions to their care.

All AgesAll Genders
27 locations

1-10 of 22

1